JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.

doi:10.1126/scisignal.aac8460

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.

Science signaling - 29 Mar 2016

Gao Sizhi P, Chang Qing, Mao Ninghui, Daly Laura A, Vogel Robert, Chan Tyler, Liu Shu Hui, Bournazou Eirini, Schori Erez, Zhang Haiying, Brewer Monica Red, Pao William, Morris Luc, Ladanyi Marc, Arcila Maria, Manova-Todorova Katia, de Stanchina Elisa, Norton Larry, Levine Ross L, Altan-Bonnet Gregoire, Solit David, Zinda Michael, Huszar Dennis, Lyden David, Bromberg Jacqueline F

Abstract excerpt

Lung adenocarcinomas with mutant epidermal growth factor receptor (EGFR) respond to EGFR-targeted tyrosine kinase inhibitors (TKIs), but resistance invariably occurs. We found that the Janus kinase (JAK)/signal transduction and activator of transcription 3 (STAT3) signaling pathway was aberrantly increased in TKI-resistant EGFR-mutant non-small cell lung cancer (NSCLC) cells. JAK2 inhibition restored sensitivity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Janus Kinase 2

Share to Protein Kinase Inhibitors

Share to STAT3 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 27025877
DOI: 10.1126/scisignal.aac8460
PMCID: PMC4950506

Genes

EGFR
JAK2
SOCS5
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.PMID 27025877Read ↗

Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.Semantic proximity Read ↗

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.Semantic proximity Read ↗

STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.Semantic proximity Read ↗

JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.Semantic proximity Read ↗

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.Semantic proximity Read ↗

Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.Semantic proximity Read ↗

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.Semantic proximity Read ↗

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.Semantic proximity Read ↗

The role of JAKs and STATs in chemoresistanceSemantic proximity Read ↗

SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma.Semantic proximity Read ↗

Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma.Semantic proximity Read ↗

Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.